Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
537.65
-9.14 (-1.67%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Madrigal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $678.71. The average 1-year stock price forecast is 26.24% higher than the current stock price, while the lowest is $542 (+0.81%) and the highest is $964 (+79.30%).
Price Target: $678.71 (+26.24%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Hold Reiterates $542 → $553 | Hold | Reiterates | $542 → $553 | +2.86% | Jul 22, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $644 | Buy | Maintains | $644 | +19.78% | Jul 22, 2026 |
| UBS | UBS | Buy Maintains $669 | Buy | Maintains | $669 | +24.43% | Jul 21, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $737 → $739 | Buy | Maintains | $737 → $739 | +37.45% | Jul 17, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jul 14, 2026 |
Financial Forecast
Revenue This Year
1.50B
from 958.40M
Increased by 56.35%
Revenue Next Year
2.18B
from 1.50B
Increased by 45.46%
EPS This Year
-6.52
from -12.73
EPS Next Year
12.38
from -6.52
EPS and Forward PE are based on non-GAAP adjusted numbers.